CAMBRIDGE, Mass., and SAN DIEGO, Nov. 11 /PRNewswire-FirstCall/ -- Biogen,
Inc. (Nasdaq: BGEN) and IDEC Pharmaceuticals Corporation (Nasdaq: IDPH)
announced today that IDEC's Chairman and Chief Executive Officer, William H.
Rastetter, Ph.D., and Biogen's Chief Financial Officer, Peter Kellogg, will
make a presentation at the Credit Suisse First Boston Healthcare Conference on
Thursday, November 13, 2003 at 9:00 a.m. Mountain Time (MT) at The Arizona
Biltmore Resort in Phoenix, Arizona.
(Logo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Assuming the merger between IDEC and Biogen is approved by shareholders at
Special Meetings on Wednesday, November 12, held in San Diego and Cambridge,
respectively, Mr. Rastetter and Mr. Kellogg would give a presentation about
the new Biogen Idec.
The presentation will be webcast live and is accessible by using the link
provided in the investor relations section of Biogen's (http://www.biogen.com) and
IDEC's (http://www.idecpharm.com) websites.
About Biogen
Biogen is the world's oldest independent biotechnology company and a
leader in biologics research, development and manufacturing. A pioneer in
leading edge research in immunology, neurobiology and oncology, Biogen brings
novel therapies to improve patients' lives around the world through its global
marketing capabilities.
About IDEC Pharmaceuticals
IDEC is a leader in the discovery, development, and commercialization of
targeted immunotherapies for the treatment of cancer and autoimmune diseases.
IDEC discovered and developed the first commercially available
radioimmunotherapy product (Zevalin(R)) approved in the United States, which
is used to treat certain non-Hodgkin's lymphomas. IDEC also discovered and,
with co-promotion partner Genentech, Inc., developed the first monoclonal
antibody product (Rituxan(R)) approved in the United States for the treatment
of cancer. Rituxan is approved in over 70 countries worldwide and is also used
to treat various types of non-Hodgkin's lymphomas. IDEC is a San Diego-based,
integrated biopharmaceutical company with multiple products in clinical stage
development and strategic alliances in a variety of research platforms.
Contact:
Rob Jacobson
Investor Relations Specialist
Biogen, Inc.
617/679-3710
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
http://www.idecpharm.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Rob Jacobson, Investor Relations Specialist
of Biogen, +1-617-679-3710
|
